2026-03-05T12:17:55Z https://kanazawa-u.repo.nii.ac.jp/oai

oai:kanazawa-u.repo.nii.ac.jp:00056420 2024-06-20T07:24:44Z 1132:1133:1134

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma 前田, 大地 Shiraishi, Kouya Okada, Yukinori Takahashi, Atsushi Kamatani, Yoichiro Momozawa, Yukihide Ashikawa, Kyota Kunitoh, Hideo Matsumoto, Shingo Takano, Atsushi Shimizu, Kimihiro Goto, Akiteru Tsuta, Koji Watanabe, Shun-ichi Ohe, Yuichiro Watanabe, Yukio Goto, Yasushi Nokihara, Hiroshi Furuta, Koh Yoshida, Akihiko Goto, Koichi Hishida, Tomoyuki Tsuboi, Masahiro Tsuchihara, Katsuya Miyagi, Yohei Tanaka, Kazumi Nakayama, Haruhiko Yokose, Tomoyuki Nagashima, Toshiteru Ohtaki, Yoichi 30585500 Maeda, Daichi Imai, Kazuhiro Minamiya, Yoshihiro Sakamoto, Hiromi Saito, Akira Shimada, Yoko Sunami, Kuniko Saito, Motonobu Inazawa, Johji Nakamura, Yusuke Yoshida, Teruhiko Yokota, Jun Matsuda, Fumihiko Matsuo, Keitaro Daigo, Yataro Kubo, Michiaki Kohno, Takashi Copyright © Nature Research / Nature Publishing Group Lung adenocarcinoma driven by somatic EGFR mutations is more prevalent in East Asians (30-50%) than in European/Americans (10-20%). Here we investigate genetic factors underlying the risk of this disease by conducting a genome-wide association study, followed by two validation studies, in 3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls. Four loci, 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63) and 17q24.2 (BPTF), previously shown to be strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma. In addition, two additional loci, HLA class II at 6p21.32 (rs2179920; P =5.1 × 10 '17, per-allele OR=1.36) and 6p21.1 (FOXP4) (rs2495239; P=3.9 × 10 '9, per-allele OR=1.19) were newly identified as loci associated with EGFR mutation-positive lung adenocarcinoma. This study indicates that multiple genetic factors underlie the risk of lung adenocarcinomas with EGFR mutations. 金沢大学医薬保健研究域医学系 Nature Publishing Group 2016-08-09 2021-06-28 eng journal article VoR https://doi.org/10.24517/00062694 http://hdl.handle.net/2297/00062694 https://kanazawa-u.repo.nii.ac.jp/records/56420 10.24517/00062694 10.1038/ncomms12451 http://www.nature.com/ncomms/index.html http://www.nature.com/ncomms/index.html https://www.nature.com/articles/ncomms12451 https://www.nature.com/articles/ncomms12451 AA12645905 2041-1723 Nature Research 7 12451 https://kanazawa-u.repo.nii.ac.jp/record/56420/files/ME-PR-MAEDA-D-12451.pdf application/pdf 542.0 kB 2021-06-28